Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 10/20 | 0.61 |
| ▸ | WIZ | O95785 | 5/20 | 0.56 |
| ▸ | IKZF2 | Q9UKS7 | 5/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20120388 | 0.94 | CRBN (0.59) | CRBNWIZIKZF2CSNK1A1 | |
| SCHEMBL20231099 | 0.91 | CRBN (0.62) | CRBNWIZIKZF2CSNK1A1 | |
| SCHEMBL20046456 | 0.91 | CRBN (0.62) | CRBNWIZIKZF2CSNK1A1 | |
| SCHEMBL34466761 | 0.88 | CRBN (0.65) | CRBNWIZIKZF2CSNK1A1 | |
| SCHEMBL34465960 | 0.88 | CRBN (0.65) | CRBNWIZIKZF2CSNK1A1 | |
| SCHEMBL25988439 | 0.87 | CRBN (0.70) | CRBNWIZIKZF2 | |
| SCHEMBL31134607 | 0.87 | CRBN (0.67) | CRBNWIZIKZF2CSNK1A1 | |
| SCHEMBL24816729 | 0.87 | CRBN (0.64) | CRBNWIZIKZF2CSNK1A1 | |
| SCHEMBL22962697 | 0.87 | CRBN (0.66) | CRBNWIZIKZF2CSNK1A1 | |
| SCHEMBL25087626 | 0.87 | CRBN (0.61) | CRBNWIZIKZF2CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-15 | — | — | US | disclosed |
| EP-4225749-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | Cullgen (Shanghai), Inc. (CN) | 2023-08-16 | — | — | EP | disclosed |
| CN-116583509-A | Compounds and methods for treating cancer | 上海睿跃生物科技有限公司 | 2023-08-11 | — | — | CN | disclosed |
| WO-2022073469-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022073469-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GGT1, VHL | CRBN 1484/4885WIZ 4872/4885IKZF2 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.